Loading...
•
Mar 31
ANI Pharmaceuticals Q1 2025 Earnings Report
Reported record first quarter 2025 financial results and raised 2025 guidance
Key Takeaways
ANI Pharmaceuticals reported record financial results for the first quarter of 2025, including record net revenues, adjusted EBITDA, and adjusted EPS. Performance was driven by strong demand for Cortrophin Gel and exceptional growth in the Generics business, leading the company to raise its full-year 2025 guidance.
Achieved record quarterly net revenues of $197.1 million, representing year-over-year growth of 43.4%.
Delivered record quarterly adjusted non-GAAP EBITDA of $50.7 million, an increase of 34.9% year-over-year.
Reported record adjusted non-GAAP diluted earnings per share of $1.70.
Cortrophin Gel net revenues increased by 43.1% to $52.9 million, driven by increased volume.
Generics net revenues increased by 40.5% year-over-year to $98.7 million, driven by new product launches and base business execution.
ANI Pharmaceuticals
ANI Pharmaceuticals
ANI Pharmaceuticals Revenue by Segment
Revenue by Segment
Cortrophin Gel Revenue
CapyFin.comILUVIEN and YUTIQ Revenue
CapyFin.comRare Disease Total Revenue
CapyFin.comBrands Revenue
CapyFin.comGeneric Pharmaceutical Products Revenue
CapyFin.comRoyalties and Other Revenue
CapyFin.comGenerics and Other Total Revenue
CapyFin.com Forward Guidance
ANI Pharmaceuticals increased its full-year 2025 guidance for net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted earnings per share.
Positive Outlook
- Increased 2025 net revenue guidance to $768.0 million - $793.0 million.
- Increased 2025 adjusted non-GAAP EBITDA guidance to $195.0 million - $205.0 million.
- Increased 2025 adjusted non-GAAP diluted EPS guidance to $6.27 - $6.62.
- Expects Rare Disease net revenues to represent 47% to 48% of total Company net revenues in 2025.
- Expects Purified Cortrophin Gel net revenues of $265.0 million to $274.0 million in 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income